Distribution and Antibiotic Susceptibility Pattern of Multidrug-Resistant Bacteria and Risk Factors Among Kidney Transplantation Recipients with Infections Over 13 Years: A Retrospective Study

References

• Freire MP, Mendes CV, Piovesan AC, et al. Does the urinary tract infection caused by carbapenem-resistant gram-negative bacilli impact the outcome of kidney transplant recipients? Transpl Infect Dis. 2018;20(4):e12923. doi:10.1111/tid.1292329797681
   PubMed Web of Science ®Google Scholar
• Al-Hasan MN, Razonable RR, Kremers WK, Baddour LM. Impact of Gram-negative bloodstream infection on long-term allograft survival after kidney transplantation. Transplantation. 2011;91(11):1206–1210. doi:10.1097/TP.0b013e318218053521494179
   PubMed Web of Science ®Google Scholar
• Brakemeier S, Taxeidi SI, Zukunft B, et al. Extended-spectrum beta-lactamase-producing enterobacteriaceae-related urinary tract infection in kidney transplant recipients: risk factors, treatment, and long-term outcome. Transplant Proc. 2017;49(8):1757–1765. doi:10.1016/j.transproceed.2017.06.03328923621
   PubMed Web of Science ®Google Scholar
• Jackson KR, Motter JD, Bae S, et al. Characterizing the landscape and impact of infections following kidney transplantation. Am J Transplant. 2020;21(1):198–207.32506639
   PubMed Web of Science ®Google Scholar
• Kinnunen S, Karhapaa P, Juutilainen A, Finne P, Helantera I. Secular trends in infection-related mortality after kidney transplantation. Clin J Am Soc Nephrol. 2018;13(5):755–762. doi:10.2215/CJN.1151101729622669
   PubMed Web of Science ®Google Scholar
• Aydin S, Patil A, Desai M, Simforoosh N. Five compelling UTI questions after kidney transplant. World J Urol. 2020;38(11):2733–2742. doi:10.1007/s00345-020-03173-432266510
   PubMed Web of Science ®Google Scholar
• Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14(2):198–205. doi:10.1111/j.1399-3062.2011.00688.x22093103
   PubMed Web of Science ®Google Scholar
• Dowzicky M, Park C. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther. 2008;30(11):2040–2050. doi:10.1016/j.clinthera.2008.11.00619108792
   PubMed Web of Science ®Google Scholar
• Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006;20(4):401–409. doi:10.1111/j.1399-0012.2006.00519.x16842513
   PubMed Web of Science ®Google Scholar
• Alevizakos M, Nasioudis D, Mylonakis E. Urinary tract infections caused by ESBL-producing Enterobacteriaceae in renal transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2017;19(6):e12759. doi:10.1111/tid.12759
   Web of Science ®Google Scholar
• Bodro M, Sabé N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96(9):843–849. doi:10.1097/TP.0b013e3182a049fd23883973
   PubMed Web of Science ®Google Scholar
• Illesy L, Szabo-Pap M, Toth F, et al. Bacterial infections after kidney transplantation: a single-center experience. Transplant Proc. 2016;48(7):2540–2543. doi:10.1016/j.transproceed.2016.07.01127742343
   PubMed Web of Science ®Google Scholar
• Hemmersbach-Miller M, Alexander BD, Sudan DL, Pieper C, Schmader KE. Single-center analysis of infectious complications in older adults during the first year after kidney transplantation. Eur J Clin Microbiol Infect Dis. 2019;38(1):141–148. doi:10.1007/s10096-018-3405-530353487
   PubMed Web of Science ®Google Scholar
• Yalci A, Celebi ZK, Ozbas B, et al. Evaluation of infectious complications in the first year after kidney transplantation. Transplant Proc. 2015;47(5):1429–1432. doi:10.1016/j.transproceed.2015.04.05626093735
   PubMed Web of Science ®Google Scholar
• Lee JR, Bang H, Dadhania D, et al. Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: a single-center report of 1166 kidney allograft recipients. Transplantation. 2013;96(8):732–738. doi:10.1097/TP.0b013e3182a0499723917724
   PubMed Web of Science ®Google Scholar
• Wu X, Dong Y, Liu Y, et al. The prevalence and predictive factors of urinary tract infection in patients undergoing renal transplantation: a meta-analysis. Am J Infect Control. 2016;44(11):1261–1268. doi:10.1016/j.ajic.2016.04.22227311513
   PubMed Web of Science ®Google Scholar
• Magruder M, Sholi AN, Gong C, et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun. 2019;10(1):5521. doi:10.1038/s41467-019-13467-w31797927
   PubMed Web of Science ®Google Scholar
• Fishman JA. Introduction: infection in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S3–6. doi:10.1111/j.1600-6143.2009.02887.x20070692
   PubMed Web of Science ®Google Scholar
• Leitheiser S, Harner A, Waller JL, et al. Risk factors associated with invasive fungal infections in kidney transplant patients. Am J Med Sci. 2020;359(2):108–116. doi:10.1016/j.amjms.2019.10.00831836132
   PubMed Web of Science ®Google Scholar
• Moreno A, Cervera C, Gavalda J, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant. 2007;7(11):2579–2586. doi:10.1111/j.1600-6143.2007.01964.x17868067
   PubMed Web of Science ®Google Scholar
• Kalil A, Syed A, Rupp M, et al. Is bacteremic sepsis associated with higher mortality in transplant recipients than in nontransplant patients? A matched case-control propensity-adjusted study. Clin Infect Dis. 2015;60(2):216–222. doi:10.1093/cid/ciu78925301215
   PubMed Web of Science ®Google Scholar
• Shendi AM, Wallis G, Painter H, Harber M, Collier S. Epidemiology and impact of bloodstream infections among kidney transplant recipients: a retrospective single-center experience. Transpl Infect Dis. 2018;20(1):e12815. doi:10.1111/tid.12815
   Web of Science ®Google Scholar
• Halaji M, Shahidi S, Atapour A, Ataei B, Feizi A, Havaei SA. Characterization of extended-spectrum beta-lactamase-producing uropathogenic Escherichia coli among Iranian kidney transplant patients. Infect Drug Resist. 2020;13:1429–1437. doi:10.2147/IDR.S24857232523361
   PubMed Web of Science ®Google Scholar
• Anesi JA, Lautenbach E, Tamma PD, et al. Risk factors for extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infection among solid organ transplant recipients. Clin Infect Dis. 2020;72(6):953–960.
   Web of Science ®Google Scholar
• Alevizakos M, Kallias A, Flokas ME, Mylonakis E. Colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae in solid organ transplantation: a meta-analysis and review. Transpl Infect Dis. 2017;19(4):e12718. doi:10.1111/tid.12718
   Web of Science ®Google Scholar
• Sadeghi A, Halaji M, Fayyazi A, Havaei SA. Characterization of plasmid-mediated quinolone resistance and serogroup distributions of uropathogenic Escherichia coli among Iranian kidney transplant patients. Biomed Res Int. 2020;2020:2850183. doi:10.1155/2020/285018333195692
   PubMed Web of Science ®Google Scholar
• Johnson JR, Orskov I, Orskov F, et al. O, K, and H antigens predict virulence factors, Carboxylesterase B pattern, antimicrobial resistance, and host compromise among Escherichia coli strains causing urosepsis. J Infect Dis. 1994;169(1):119–126. doi:10.1093/infdis/169.1.1197506278
   PubMed Web of Science ®Google Scholar
• Overdevest IT, Bergmans AM, Verweij JJ, et al. Prevalence of phylogroups and O25/ST131 in susceptible and extended-spectrum beta-lactamase-producing Escherichia coli isolates, the Netherlands. Clin Microbiol Infect. 2015;21(6):570 e571–574. doi:10.1016/j.cmi.2015.02.02025749563
   PubMedGoogle Scholar
• Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2). doi:10.1128/CMR.00079-17
   Web of Science ®Google Scholar
• Ng TM, Khong WX, Harris PN, et al. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing enterobacteriaceae. PLoS One. 2016;11(4):e0153696. doi:10.1371/journal.pone.015369627104951
   PubMed Web of Science ®Google Scholar
• Sharara SL, Amoah J, Pana ZD, Simner PJ, Cosgrove SE, Tamma PD. Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum beta-lactamase-producing organisms? Clin Infect Dis. 2020;71(8):e331–e337. doi:10.1093/cid/ciz120531859352
   PubMed Web of Science ®Google Scholar
• Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of beta-lactam/beta-lactamase inhibitor combinations for Treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(7):4159–4169. doi:10.1128/AAC.00365-1627139473
   PubMed Web of Science ®Google Scholar
• Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015;60(9):1319–1325. doi:10.1093/cid/civ00325586681
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793–2803. doi:10.1093/jac/dks30122915465
   PubMed Web of Science ®Google Scholar
• Sfeir MM, Askin G, Christos P. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis. Int J Antimicrob Agents. 2018;52(5):554–570. doi:10.1016/j.ijantimicag.2018.07.02130081138
   PubMed Web of Science ®Google Scholar
• Pierrotti LC, Perez-Nadales E, Fernandez-Ruiz M, et al. Efficacy of beta-lactam/beta-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project). Transpl Infect Dis. 2020;23(3)e13520.
   Web of Science ®Google Scholar
• Wang J, Li X, Wu X, et al. Fecal microbiota transplantation as an effective treatment for carbapenem-resistant Klebsiella pneumoniae infection in a renal transplant patient. Infect Drug Resist. 2021;14:1805–1811. doi:10.2147/IDR.S30830834017186
   PubMed Web of Science ®Google Scholar
• Grosen AK, Povlsen JV, Lemming LE, Jorgensen SMD, Dahlerup JF, Hvas CL. Faecal microbiota transplantation eradicated extended-spectrum beta-lactamase-producing Klebsiella pneumoniae from a renal transplant recipient with recurrent urinary tract infections. Case Rep Nephrol Dial. 2019;9(2):102–107. doi:10.1159/00050233631559265
   PubMed Web of Science ®Google Scholar
• Falagas ME, Fragoulis KN, Bliziotis IA. Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failure–a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2006;21(9):2536–2542. doi:10.1093/ndt/gfl23516705024
   PubMed Web of Science ®Google Scholar
• Lora-Tamayo J, Murillo O, Iribarren JA, et al. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis. 2013;56(2):182–194. doi:10.1093/cid/cis74622942204
   PubMed Web of Science ®Google Scholar
• Schrenzel J, Harbarth S, Schockmel G, et al. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis. 2004;39(9):1285–1292. doi:10.1086/42450615494904
   PubMed Web of Science ®Google Scholar
• Jung YJ, Koh Y, Hong SB, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med. 2010;38(1):175–180. doi:10.1097/CCM.0b013e3181b9ecea20050336
   PubMed Web of Science ®Google Scholar
• Hamid R, Javaid S, Khan M, Lal N, Luxmi S, Sarfaraz S. Multiple drug resistant urinary tract infection in kidney transplant recipients: a retrospective cohort study. Saudi J Kidney Dis Transplant. 2020;31(5):905–916. doi:10.4103/1319-2442.301197
   Web of Science ®Google Scholar
• Linares L, Cervera C, Cofan F, et al. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transplant Proc. 2007;39(7):2222–2224. doi:10.1016/j.transproceed.2007.06.06117889144
   PubMed Web of Science ®Google Scholar
• Yuan X, Liu T, Wu D, Wan Q. Epidemiology, susceptibility, and risk factors for acquisition of MDR/XDR Gram-negative bacteria among kidney transplant recipients with urinary tract infections. Infect Drug Resist. 2018;11:707–715. doi:10.2147/IDR.S16397929785131
   PubMed Web of Science ®Google Scholar